Almotriptan Malate

CHEMBL1200521 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
469.6 g/mol
LogP
Phase
4

The malate salt form of almotriptan, a serotonin 5-HT1B/1D receptor agonist used to treat acute migraine attacks with or without aura. This salt formulation provides the same mechanism of cerebrovascular constriction and pain pathway inhibition for effective migraine relief.

Peso molecular

469,6000 g/mol

TPSA

160,00 Ų

Áreas terapéuticas

Mecanismo de acción

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12.O=C(O)CC(O)C(=O)O

InChI

InChI=1S/C17H25N3O2S.C4H6O5/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20;5-2(4(8)9)1-3(6)7/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3;2,5H,1H2,(H,6,7)(H,8,9)

Molecular Formula

C21H31N3O7S

HBD / HBA

4 / 9

Enlaces Rotables

9

Átomos Pesados

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

The malate salt form of almotriptan, a serotonin 5-HT1B/1D receptor agonist used to treat acute migraine attacks with or without aura. This salt formulation provides the same mechanism of cerebrovascular constriction and pain pathway inhibition for effective migraine relief.

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Yes, Almotriptan Malate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200521. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 123607. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.